<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970723</url>
  </required_header>
  <id_info>
    <org_study_id>P071227-AOM 08077</org_study_id>
    <nct_id>NCT00970723</nct_id>
  </id_info>
  <brief_title>High Blood Pressure and Sleep Apnea in Diabetic Macular Edema</brief_title>
  <acronym>OMHADIA</acronym>
  <official_title>Role of High Blood Pressure and Sleep Apnea in Type 2 Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macular edema remains a major cause of vision impairment in diabetic patients. Its
      pathogenesis is multifactorial and incompletely understood. Systemic factors seam to play a
      role in this pathogenesis, including high blood pressure. The objective of the study is to
      evaluate the effect of an intensified intervention on blood pressure and sleep apnea with
      that of conventional treatment in patients with type 2 diabetes and diabetic macular edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with type 2 diabetes and macular edema involving the center of the macula in both
      eyes will be randomly assigned to receive conventional treatment in accordance with national
      guidelines or to receive intensive treatment, with a systematic screening for sleep apnea and
      /or uncontrolled high blood pressure, and intensified intervention on both anomalies if
      detected. The primary outcome will be the percentage of patients having a sustained 50% or
      more-decrease in retinal thickening at 1 year. Secondary outcomes will be the percentage of
      patients having a 2 ETDRS lines or more-increase in visual acuity at one year, number of
      ocular interventions in each group, prevalence of sleep apnea and uncontrolled high blood
      pressure in the intervention group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be the percentage of patients having a sustained 50% or more-decrease in retinal thickening at 1 year, assessed with OCT in the study eye.</measure>
    <time_frame>M13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients having a 2 ETDRS lines or more-increase in visual acuity at one year in the study eye</measure>
    <time_frame>M13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ocular interventions (laser photocoagulation, intra ocular injections) in each group at one year in the study eye</measure>
    <time_frame>M6-9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of diabetic retinopathy in each group at one year according to the International DR classification in the study eye</measure>
    <time_frame>M13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of blood pressure in each group at one year</measure>
    <time_frame>M13</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>intensive treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>with a systematic screening for sleep apnea and/or uncontrolled high blood pressure, and intensified intervention on both anomalies if detected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>in accordance with national guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>high blood pressure treatment</intervention_name>
    <description>over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months</description>
    <arm_group_label>intensive treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>sleep apnea treatment</intervention_name>
    <description>over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months</description>
    <arm_group_label>intensive treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>diabetic macular edema treatment</intervention_name>
    <description>over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months</description>
    <arm_group_label>intensive treatment</arm_group_label>
    <arm_group_label>conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with type 2 diabetes, aged 18 years or more

          -  Bilateral diabetic macular edema involving the center of the macula with central
             retinal thickness 300 µm or more

        Exclusion Criteria:

          -  Patient with type 1 diabetes

          -  Tractional macular edema

          -  Patient with renal insufficiency : clearance of creatinin &lt; 30 ml/min according to
             COCROFT or MDRD, patient under dialysis

          -  Other causes for macular edema (uveitis, epiretinal membrane)

          -  Proliferative diabetic retinopathy requiring panretinal photocoagulation at inclusion

          -  Cataract surgery or panretinal photocoagulation during the 6 months before inclusion,
             laser photocoagulation at the posterior pole or intra ocular steroid injection during
             the 3 months before inclusion

          -  Any ocular condition precluding access to the posterior pole, or ocular pathologies
             not related to diabetes (age related macular degeneration venous occlusion…)

          -  Previous vitrectomy in the eyes

          -  Pregnant or breast-feeding female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale MASSIN, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'ophtalmologie, Hôpital de la Vision, La Timone</name>
      <address>
        <city>Marseille</city>
        <state>Bouches du Rhone</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Ophtalmologie, Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <state>Ile de france</state>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière, service d'Ophtalmologie</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Ophtalmologie IV, Hôpital des XV-XX</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Ophtalmologie, Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <state>Loire Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Paques M, Massin P, Sahel JA, Gaudric A, Bergmann JF, Azancot S, Lévy BI, Vicaut E. Circadian fluctuations of macular edema in patients with morning vision blurring: correlation with arterial pressure and effect of light deprivation. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4707-11.</citation>
    <PMID>16303968</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>April 11, 2014</last_update_submitted>
  <last_update_submitted_qc>April 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>Macula edema</keyword>
  <keyword>Sleep apnea</keyword>
  <keyword>High blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

